MARKET

AKRO

AKRO

Akero Therapeutics
NASDAQ
27.81
+0.82
+3.04%
After Hours: 28.28 +0.47 +1.69% 19:59 03/01 EST
OPEN
27.40
PREV CLOSE
26.99
HIGH
30.47
LOW
27.07
VOLUME
2.72M
TURNOVER
0
52 WEEK HIGH
58.38
52 WEEK LOW
11.25
MARKET CAP
1.55B
P/E (TTM)
-11.8094
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $43
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Akero Therapeutics (AKRO)
TipRanks · 1d ago
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
NASDAQ · 1d ago
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
NASDAQ · 1d ago
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
NASDAQ · 2d ago
Akero Therapeutics’ Buy Rating Affirmed on Efruxifermin’s Promise for NASH Treatment
TipRanks · 2d ago
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
NASDAQ · 2d ago
Akero Therapeutics: Q4 Earnings Insights
Akero Therapeutics reported its Q4 earnings on February 29. The company missed estimates by -15.0%. The company's revenue was down $0 from the same period last year. AkeroTherapeutics is expected to report its earnings on Thursday morning.
Benzinga · 2d ago
More
About AKRO
Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.

Webull offers Akero Therapeutics Inc stock information, including NASDAQ: AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.